Enlivex Therapeutics (Enlivex Therapeutics) Total Current Assets : $33.76 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Enlivex Therapeutics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Enlivex Therapeutics's total current assets for the quarter that ended in Dec. 2023 was $33.76 Mil.

Enlivex Therapeutics Total Current Assets Historical Data

The historical data trend for Enlivex Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Total Current Assets Chart

Enlivex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

16.42

38.12

86.44

52.33

33.76

Enlivex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															52.33	37.58	30.79	31.84	33.76

Enlivex Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Enlivex Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	27.32	+	0.229	+	0	+	6.215
	=	33.76

Enlivex Therapeutics's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	27.32	+	0.229	+	0	+	6.215
	=	33.76

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Enlivex Therapeutics (NAS:ENLV) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Enlivex Therapeutics's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	27.32	-	6.747	+	0.75 * 0	+	0.5 * 0
=	20.57

Enlivex Therapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Enlivex Therapeutics (Enlivex Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (NAS:ENLV) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

ENLV:Israel 1BT:Germany

Address

14 Einstein Street, Nes Ziona, ISR, 7403618

Website

https://www.enlivex.com

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.